吉西他滨联合白蛋白结合型紫杉醇或 FOLFIRINOX 治疗转移性胰腺癌患者后二线化疗的疗效。
Efficacy of second-line chemotherapy after treatment with gemcitabine plus nab-paclitaxel or FOLFIRINOX in patients with metastatic pancreatic cancer.
发表日期：2023 Nov 08
作者：
Masaru Fukahori, Yoshinobu Okabe, Mototsugu Shimokawa, Taiga Otsuka, Futa Koga, Yujiro Ueda, Junichi Nakazawa, Azusa Komori, Satoshi Otsu, Shiho Arima, Akitaka Makiyama, Hiroki Taguchi, Takuya Honda, Tomoyuki Ushijima, Keisuke Miwa, Taro Shibuki, Kenta Nio, Yasushi Ide, Norio Ureshino, Toshihiko Mizuta, Kenji Mitsugi, Tsuyoshi Shirakawa
来源：
Best Pract Res Cl Ob
摘要：
转移性胰腺癌 (MPC) 患者的一线化疗包括吉西他滨联合白蛋白结合型紫杉醇 (GnP) 和 FOLFIRINOX (FFX)。然而，二线化疗的疗效以及联合化疗在临床中的作用仍不清楚。数据收集自 2013 年 12 月至 2017 年 3 月日本九州地区的 14 家医院。比较了接受二线化疗的患者（CT 组）和接受二线化疗的患者的中位总生存期 (mOS)。最佳支持治疗（BSC 组）。此外，还对 CT 组中联合化疗的 mOS 与单一化疗进行了比较。为了控制治疗选择中可能存在的偏差，我们进行了倾向评分调整分析。共有 255 名患者接受 GnP 或 FFX 作为一线化疗。其中CT组有156例，BSC组有77例。 CT 组的 mOS 明显长于 BSC 组（5.2 个月与 2.6 个月；调整后的风险比 (HR) 0.38；95% CI 0.27-0.54）。在CT组中，89名患者接受联合化疗，67名患者接受单一化疗。联合化疗组和单一化疗组之间的 mOS 没有显着差异（5.5 个月与 4.8 个月；调整后 HR 0.88；95% CI 0.58-1.33）。在接受二线治疗的 MPC 患者中，CT 组的 mOS 显着长于 BSC 组，但与单一化疗相比，联合化疗并没有改善生存率。© 2023。作者。
First-line chemotherapy for patients with metastatic pancreatic cancer (MPC) includes gemcitabine plus nab-paclitaxel (GnP) and FOLFIRINOX (FFX). However, the efficacy of second-line chemotherapy and the role of combination chemotherapy in clinical practice is still unknown. Data was gathered from 14 hospitals in the Kyushu area of Japan from December 2013 to March 2017. The median overall survival (mOS) from second-line treatment was contrasted between patients who received second-line chemotherapy (CT group) and those who received the best supportive care (BSC group). Furthermore, the mOS of combination chemotherapy was compared to mono chemotherapy in the CT group. To control possible bias in the selection of treatment, we performed a propensity score-adjusted analysis. A total of 255 patients received GnP or FFX as first-line chemotherapy. There were 156 in the CT group and 77 in the BSC group of these. The CT group had a significantly longer mOS than the BSC group (5.2 vs. 2.6 months; adjusted hazard ratio (HR) 0.38; 95% CI 0.27-0.54). In the CT group, 89 patients received combination chemotherapy while 67 received mono chemotherapy. The mOS did not differ significantly between the combination and mono chemotherapy groups (5.5 vs. 4.8 months; adjusted HR 0.88; 95% CI 0.58-1.33). Among patients with MPC receiving second-line treatment, the CT group had a significantly longer mOS than the BSC group, but combination chemotherapy conferred no improvement in survival compared to mono chemotherapy.© 2023. The Author(s).